Research programme: substance P analogues - New Amsterdam Sciences
Alternative Names: Neurokinin-1 receptor agonists - New Amsterdam SciencesLatest Information Update: 25 Apr 2023
At a glance
- Originator New Amsterdam Sciences
- Developer National Institutes of Health (USA); New Amsterdam Sciences
- Class Peptides
- Mechanism of Action Immunostimulants; Neurokinin 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Idiopathic pulmonary fibrosis; Influenza virus infections
- Discontinued Acute radiation syndrome; Diabetic foot ulcer
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Acute radiation syndrome in USA (PO) before April 2023 (New Amsterdam Sciences pipeline, April 2023)
- 25 Apr 2023 Discontinued - Preclinical for Diabetic foot ulcer in USA (unspecified route) before April 2023 (New Amsterdam Sciences pipeline, April 2023)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in USA (PO)